SG11201804405PA - Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration - Google Patents

Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration

Info

Publication number
SG11201804405PA
SG11201804405PA SG11201804405PA SG11201804405PA SG11201804405PA SG 11201804405P A SG11201804405P A SG 11201804405PA SG 11201804405P A SG11201804405P A SG 11201804405PA SG 11201804405P A SG11201804405P A SG 11201804405PA SG 11201804405P A SG11201804405P A SG 11201804405PA
Authority
SG
Singapore
Prior art keywords
international
pennsylvania
nanoceria
microrna
conjugate
Prior art date
Application number
SG11201804405PA
Inventor
Kenneth Liechty
Sudipta Seal
Robert Gorman
Original Assignee
Univ Colorado Regents
University Of Central Florida Research Foundation Inc
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Colorado Regents, University Of Central Florida Research Foundation Inc, Univ Pennsylvania filed Critical Univ Colorado Regents
Publication of SG11201804405PA publication Critical patent/SG11201804405PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
    • C01F17/00—Compounds of rare earth metals
    • C01F17/20—Compounds containing only rare earth metals as the metal element
    • C01F17/206—Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion
    • C01F17/224—Oxides or hydroxides of lanthanides
    • C01F17/235—Cerium oxides or hydroxides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -' Organization International Bureau (43) International Publication Date ..... .....r .,„01 1 June 2017 (01.06.2017) WIPO I PCT ID Hit (10) 1111111111111111111 WO International Ell 2017/091700 11111111101 Publication 1111111111111111 Number Al RIO IIII IIIIIIII (51) International Patent Classification: lando, Florida 32826 (US). GORMAN, Robert; do Uni- A61K 9/51 (2006.01) C12N 15/113 (2010.01) versity of Pennsylvania, Penn Center for Innovation, 3160 A61K 33/24 (2006.01) Chestnut Street, Suite 200, Philadelphia, Pennsylvania 19104 (US). (21) International Application Number: PCT/US2016/063540 (74) Agents: EWING, James F. et al.; Foley & Lardner LLP, (22) International Filing Date: 3000 K. Street, N.W., Suite 600, Washington, District of 23 November 2016 (23.11.2016) Columbia 20007 (US). (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (30) Priority Data: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 62/259,909 25 November 2015 (25.11.2015) US HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 62/378,997 24 August 2016 (24.08.2016) US KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (71) Applicants . THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE [US/US]; OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 1800 Grant Street, 8th Floor, Denver, Colorado 80203 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (US). UNIVERSITY OF CENTRAL FLORIDA RE- SEARCH FOUNDATION, INC. [US/US]; 12201 Re- ZW. search Parkway, Ste 501, Orlando, Florida 32826 (US). (84) Designated States (unless otherwise indicated, for every THE TRUSTEES THE OF UNIVERSITY OF kind of regional available): ARIPO (BW, GH, protection PENNSYLVANIA [US/US]; Penn Center for Innovation, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 3160 Chestnut Street, Suite 200, Philadelphia, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Pennsylvania 19104 (US). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (72) Inventors: LIECHTY, Kenneth; 12631 E. 17th Avenue, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Aurora, Colorado 80045 (US). SEAL, Sudipta; Uni- c/o SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, versity of Central Florida, 12201 Research Parkway, Or- GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] Title: MICRORNA-146A AND NANOCERIA TO IMPROVE WOUND HEALING AND PROMOTE (54) USE OF CONJUGATE TISSUE REGENERATION 120 -- o Non-Db + PBS __a_- Db + PBS as ---&-- Non-Db + CNPs-miR-146a 2 0 —0-- Db + CNPs-miR-146a < v C = ''' C 6 0 z 0 1-1 0 0 ‘ \ JI b - _ 0 0 IN DO D2 D4 D5 D7 D9 D1D D12 D14 D16 D19 D21 1-1 Days 01 0 HG. 30 N 1-1 O (57) : The present disclosure relates to wound treatment and therapy and the promotion of tissue regeneration following in - \" jury. In particular, it relates to a microRNA-146a and nanoceria conjugate for improving wound healing and, in some embodiments, 0 preventing adverse ventricular remodeling following myocardial infarction. WO 2017/091700 Al MIDEDItitiDEIRDEFEDIEREDIDENIMMIEDIS Declarations under Rule 4.17: Published: — as to the applicant's entitlement the earlier application (Rule 4.17 to claim (iii)) the priority of — with international search report (Art 21(3))
SG11201804405PA 2015-11-25 2016-11-23 Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration SG11201804405PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259909P 2015-11-25 2015-11-25
US201662378997P 2016-08-24 2016-08-24
PCT/US2016/063540 WO2017091700A1 (en) 2015-11-25 2016-11-23 Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration

Publications (1)

Publication Number Publication Date
SG11201804405PA true SG11201804405PA (en) 2018-06-28

Family

ID=58763692

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804405PA SG11201804405PA (en) 2015-11-25 2016-11-23 Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration

Country Status (5)

Country Link
US (1) US11833172B2 (en)
EP (1) EP3380088A4 (en)
CN (1) CN108697653B (en)
SG (1) SG11201804405PA (en)
WO (1) WO2017091700A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019040850A1 (en) * 2017-08-24 2019-02-28 The Regents Of The University Of Colorado, A Body Corporate Topical silk compositions and methods of using
CN107596381B (en) * 2017-09-21 2019-03-26 重庆市人民医院 A kind of method of hyaluronic acid mediated synthetic modification cerium nano-quantum point and products thereof and application
CN108969757B (en) * 2018-07-11 2021-07-27 浙江大学 MicroRNA-loaded cerium oxide nano composite hydrogel and preparation method and application thereof
JP7471606B2 (en) * 2018-09-28 2024-04-22 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド・ア・ボディ・コーポレイト Methods for preventing or treating pulmonary inflammation and fibrosis - Patents.com
WO2020163371A1 (en) * 2019-02-04 2020-08-13 The Regents Of The University Of Colorado, A Body Corporate Methods for preventing and treating inflammation and inflammatory disease
CN110960552B (en) * 2019-12-28 2022-04-05 天津大学 Monoatomic nano enzyme patch for skin wounds and preparation method thereof
WO2023168056A2 (en) * 2022-03-04 2023-09-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for using cerium oxide nanoparticles for macrophage-mediated efficacy in respiratory syncytial viral infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393396B2 (en) * 2002-02-14 2016-07-19 Gholam A. Peyman Method and composition for hyperthermally treating cells
US7534453B1 (en) 2002-09-05 2009-05-19 University Of Central Florida Research Foundation, Inc. Cerium oxide nanoparticles and use in enhancing cell survivability
EP1756289B1 (en) * 2004-05-24 2015-01-14 Midatech Ltd. Nanoparticles comprising rna ligands
US20100166821A1 (en) 2005-06-27 2010-07-01 Edward Via Virginia College Of Osteopathic Medicin Anti-Inflammatory, Radioprotective, and Longevity Enhancing Capabilities of Cerium Oxide Nanoparticles
EP2288258A4 (en) * 2008-04-25 2012-10-31 Univ Oklahoma Inhibition of neovascularization by cerium oxide nanoparticles
US20100098768A1 (en) 2008-10-16 2010-04-22 Clarkson University Method of neuroprotection from oxidant injury using metal oxide nanoparticles
KR102056324B1 (en) 2010-11-10 2019-12-16 인리젠 Injectable formulations for organ augmentation
US20130195927A1 (en) 2011-12-06 2013-08-01 University Of Central Florida Research Foundation Inc. Cerium oxide nanoparticles and associated methods for promoting wound healing
US9308265B2 (en) * 2012-04-17 2016-04-12 Cerion Llc Nanoparticles of cerium and amino acids
WO2013187980A1 (en) 2012-06-13 2013-12-19 Cerion Enterprises Llc Nanoceria for the treatment of oxidative stress
ITRM20120350A1 (en) 2012-07-19 2014-01-20 Univ Degli Studi Milano NANOCOSTRUTTI WITH PHARMACOLOGICAL ACTIVITY.
AU2013302799B2 (en) * 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
WO2014036429A1 (en) * 2012-08-31 2014-03-06 Aptamir Therapeutics, Inc. Mirna modulators of chronic visceral inflammation
EP2976293B1 (en) * 2013-03-18 2019-12-18 Bar-Ilan University Magnetic inorganic iron-based nanoparticles
US9623110B2 (en) 2013-08-09 2017-04-18 Cerion, Llc Nanoparticles of a metal and a nucleobase
WO2015058037A1 (en) 2013-10-17 2015-04-23 Cerion, Llc Malic acid stabilized nanoceria particles
US10048269B2 (en) * 2014-07-25 2018-08-14 SeLux Diagnostics, Inc. Assay methods involving dissociable nanoparticles
WO2016141334A2 (en) 2015-03-04 2016-09-09 The Regents Of The University Of Colorado Compositions and methods for diagnosing and treating autoimmune diseases

Also Published As

Publication number Publication date
WO2017091700A1 (en) 2017-06-01
CN108697653A (en) 2018-10-23
US11833172B2 (en) 2023-12-05
CN108697653B (en) 2021-12-31
US20180344764A1 (en) 2018-12-06
EP3380088A1 (en) 2018-10-03
EP3380088A4 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
SG11201804405PA (en) Use of microrna-146a and nanoceria conjugate to improve wound healing and promote tissue regeneration
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804134YA (en) Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG11201810161RA (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
SG11201408261UA (en) Syringe
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201407851RA (en) Synthesis of pyrrolo [2, 3 - b] pyridines
SG11201407340YA (en) Treatment of myelosuppression
SG11201805828YA (en) Method of treating c3 glomerulopathy
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201407200TA (en) Liquid formulation
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
SG11201805001UA (en) Method of treating influenza a
SG11201407812SA (en) Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives
SG11201908603PA (en) Macrocyclic compound and uses thereof
SG11201805385QA (en) Bromodomain and extra-terminal protein inhibitor combination therapy
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201805755SA (en) Methods of administering hepcidin
SG11201804220SA (en) Activated stem cells and systemic treatment methods for infected wounds
SG11201901505SA (en) I domain chimeric antigen receptor specific to icam-1